Unmasking metabolic clues: adipsin, irisin and osteopontin as biomarkers in polycystic ovary syndrome and their impact on metabolic dynamics: a case-control study
, 1, 1, 1
Abstract
Objectives: Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age, often associated with metabolic alterations. This study assessed serum levels of adipsin, irisin, and osteopontin in patients with PCOS and examined their correlations with metabolic parameters.
Material and methods: A case-control study was conducted involving 96 women with PCOS and 80 healthy controls. Serum levels of adipsin, irisin, and osteopontin were measured; demographic, clinical, and metabolic characteristics were evaluated.
Results: Patients with PCOS were significantly younger than controls (p < 0.001). The PCOS group included a significantly greater proportion of obese individuals (p = 0.013). Patients with PCOS exhibited elevated serum adipsin (p = 0.020) and reduced osteopontin (p < 0.001) levels relative to controls; obesity and age influenced these differences. Osteopontin demonstrated superior predictive power for PCOS diagnosis [area under the curve (AUC) = 0.802] compared with adipsin (AUC = 0.602). A combination of osteopontin and adipsin yielded the highest predictive value (AUC = 0.817) among double or triple biomarker combinations.
Conclusions: This study identified potential associations among adipsin, osteopontin, irisin, and PCOS. Further research is warranted to elucidate their roles and clinical implications in PCOS and its metabolic alterations. The findings highlight the impact of age and obesity on these biomarkers and their relationships with PCOS, providing insight into the syndrome's complex pathophysiology.
Keywords: polycystic ovary syndromeadipsinosteopontinirisinadipokines
References
- Martínez-García MÁ, Moncayo S, Insenser M, et al. Metabolic cytokines at fasting and during macronutrient challenges: influence of obesity, female androgen excess and sex. Nutrients. 2019; 11(11).
- Daan NMP, Koster MPH, de Wilde MA, et al. Biomarker profiles in women with PCOS and PCOS offspring; a pilot study. PLoS One. 2016; 11(11): e0165033.
- Butler AE, Moin AS, Sathyapalan T, et al. Components of the complement cascade differ in polycystic ovary syndrome. Int J Mol Sci. 2022; 23(20).
- Gursoy Calan O, Calan M, Yesil Senses P, et al. Increased adipsin is associated with carotid intima media thickness and metabolic disturbances in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2016; 85(6): 910–917.
- Kahyaoglu S, Ozaksit M, Duman GK, et al. Does baseline serum androgen levels have an impact on ovulation induction cycle outcomes by using clomifene citrate among infertile women with polycystic ovary syndrome? A retrospective cohort study. Gynecol Obstet Reproductive Med. 2023; 29(2): 122–127.
- Vejrazkova D, Lischkova O, Vankova M, et al. Distinct response of fat and gastrointestinal tissue to glucose in gestational diabetes mellitus and polycystic ovary syndrome. Physiol Res. 2017; 66(2): 283–292.
- Behboudi-Gandevani S, Hedayati M, Mansournia M, et al. The associations between serum concentrations of irisin and glucose-dependent insulinotropic polypeptide with body mass index among women with and without polycystic ovary syndrome. Int J Endocrinol Metab. 2021; 19(4): e111914.
- Weng Y, Zhang Y, Wang D, et al. Exercise-induced irisin improves follicular dysfunction by inhibiting IRE1α-TXNIP/ROS-NLRP3 pathway in PCOS. J Ovarian Res. 2023; 16(1): 151.
- Zheng Y, He J, Yang D, et al. Irisin reduces the abnormal reproductive and metabolic phenotypes of PCOS by regulating the activity of brown adipose tissue in mice. Biol Reprod. 2022; 107(4): 1046–1058.
- Cao S, Hu Y. Effects of serum irisin, neuregulin 4, and weight management on obese adolescent girls with polycystic ovary syndrome. Biosci Rep. 2021; 41(9).
- Gür FM, Timurkaan S, Yalcin MH, et al. Immunohistochemical localization of irisin in mole rats (Spalax leucodon). Biotech Histochem. 2017; 92(4): 245–251.
- Onat T, Inandiklioglu N, Kara M, et al. Increased serum myonectin and irisin levels with myonectin and FNDC5 expressions in polycystic ovary syndrome: a case control study. J Obstet Gynaecol. 2022; 42(5): 1381–1387.
- Li M, Yang M, Zhou X, et al. Elevated Circulating Levels of Irisin and the Effect of Metformin Treatment in Women With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2015; 100(4): 1485–1493.
- Wang W, Guo Y, Zhang X, et al. Abnormal irisin level in serum and endometrium is associated with metabolic dysfunction in polycystic ovary syndrome patients. Clin Endocrinol (Oxf). 2018; 89(4): 474–480.
- Alatas SE, Yavuz Dogu S, Kilic D, et al. Comparison of serum adiponectin and osteopontin levels along with metabolic risk factors between obese and lean women with and without PCOS. Endokrynol Pol. 2020; 71(6): 497–503.
- Wang Y, Zhou W, Wu C, et al. Circulating osteopontin and its association with liver fat content in non-obese women with polycystic ovary syndrome: a case control study. Reprod Biol Endocrinol. 2018; 16(1).
- Paravati R, Mello NDe, Onyido EK, et al. Differential regulation of osteopontin and CD44 correlates with infertility status in PCOS patients. J Mol Med. 2020; 98(12): 1713–1725.
- Saklamaz A, Calan M, Yilmaz O, et al. Polycystic ovary syndrome is associated with increased osteopontin levels. Eur J Endocrinol. 2016; 174(4): 415–423.
- Kwon S, Heo A, Chun S. Triglyceride and glucose index for identifying abnormal insulin sensitivity in women with polycystic ovary syndrome. Obstet Gynecol Sci. 2023; 66(4): 307–315.
- Catalán V, Gómez-Ambrosi J, Rodríguez A, et al. Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J Clin Endocrinol Metab. 2007; 92(9): 3719–3727.
- Luo P, Zhang C, He Y, et al. Several circulating biomarkers for PCOS diagnosis. Expe Clin Endocrinol Diabetes. 2019; 129(10): 705–712.
- Zhang L, Fang X, Li L, et al. The association between circulating irisin levels and different phenotypes of polycystic ovary syndrome. J Endocrinol Invest. 2018; 41(12): 1401–1407.
- Chang CL, Huang SYu, Hsu YaC, et al. The serum level of irisin, but not asprosin, is abnormal in polycystic ovary syndrome patients. Sci Rep. 2019; 9(1): 6447.
- Farhan FS, Hussien SS. Irisin as a novel marker for insulin resistance in iraqi women with polycystic ovary syndrome before and after metformin therapy. J Obstet Gynaecol India. 2019; 69(Suppl 2): 194–200.
- Lin K, Sun X, Wang X, et al. Circulating adipokine levels in nonobese women with polycystic ovary syndrome and in nonobese control women: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2021; 11.
